TP53 and breast carcinoma: Specifically, GABRB3 is an inhibitory gene of head and neck cancer [21]; SYNE1 gene hypermethylation can be used as biomarkers in colorectal [22]; SYNE1 polymorphisms are associated with the risk of developing invasive epithelial ovarian cancer [23]; intratumoral heterogeneity of HMCN1 mutant alleles is associated with poor prognosis of breast cancer patients [24]; the combination of SLITRK5 and TP53 is associated with the clinical outcome of gastric cancer patients [25].